Background: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. Objectives: To evaluate demographic, social and clinical factors that could be used to predict effectiveness and stratify response to biologic therapies in psoriasis. Methods: Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic‐naive patients starting biologics with outcome data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 putative predictors and outcomes were investigated in univariate and multivariable regression analyses. Potential stratifiers of treatment respo...
BACKGROUND:Knowledge regarding differences in care for psoriatic patients is limited. The aim of thi...
International audienceBackground - Decision-making is a complex process. The aim of our study was to...
Background: Real-life data on patients with psoriasis treated with guselkumab are few and are needed...
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. Ho...
Background: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. H...
Contains fulltext : 169670.pdf (publisher's version ) (Closed access)BACKGROUND: I...
Luis Puig1, Tao Fan,2 Qian Ding,2 Nancy E Smith2 1Department of Dermatology, Hospital de la Santa Cr...
Biologic therapies represent a significant advance in the treatment of psoriasis. However, no studie...
BACKGROUND/OBJECTIVES: Biological agents provide a relatively safe and promising long-term therapeut...
Background: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a...
BACKGROUND: The course of biological treatment in clinical practice may be highly different from tre...
Background: There are an increasing number of biologic therapies approved for the treatment of psori...
BACKGROUND:Knowledge regarding differences in care for psoriatic patients is limited. The aim of thi...
International audienceBackground - Decision-making is a complex process. The aim of our study was to...
Background: Real-life data on patients with psoriasis treated with guselkumab are few and are needed...
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. Ho...
Background: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. H...
Contains fulltext : 169670.pdf (publisher's version ) (Closed access)BACKGROUND: I...
Luis Puig1, Tao Fan,2 Qian Ding,2 Nancy E Smith2 1Department of Dermatology, Hospital de la Santa Cr...
Biologic therapies represent a significant advance in the treatment of psoriasis. However, no studie...
BACKGROUND/OBJECTIVES: Biological agents provide a relatively safe and promising long-term therapeut...
Background: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a...
BACKGROUND: The course of biological treatment in clinical practice may be highly different from tre...
Background: There are an increasing number of biologic therapies approved for the treatment of psori...
BACKGROUND:Knowledge regarding differences in care for psoriatic patients is limited. The aim of thi...
International audienceBackground - Decision-making is a complex process. The aim of our study was to...
Background: Real-life data on patients with psoriasis treated with guselkumab are few and are needed...